NovaGo Secures USD 30 Million to Advance Proof-of-Concept Study in Acute Spinal Cord Injury
NovaGo Therapeutics AG, a Swiss clinical‑stage biotechnology company, raised USD 30 million (CHF 24 million) in a Series B financing led by Neurimmune and Pureos, complemented by non‑dilutive funding from the Swiss Paraplegic Foundation and Wings for Life. The proceeds will fund a fully randomized, double‑blind proof‑of‑concept study enrolling 120 patients with acute spinal cord injury across sites in Germany, Spain, and Switzerland. The study aims to evaluate the anti‑Nogo‑A biologic NG004, which targets a protein that inhibits nerve regeneration.
NovaGo Therapeutics AG, a Swiss clinical‑stage biotechnology company, raised USD 30 million (CHF 24 million) in a Series B financing led by Neurimmune and Pureos, complemented by non‑dilutive funding from the Swiss Paraplegic Foundation and Wings for Life. The proceeds will fund a fully randomized, double‑blind proof‑of‑concept study enrolling 120 patients with acute spinal cord injury across sites in Germany, Spain, and Switzerland. The study aims to evaluate the anti‑Nogo‑A biologic NG004, which targets a protein that inhibits nerve regeneration.
The funding and clinical advancement highlight Switzerland’s robust biotech ecosystem, which increasingly integrates AI-driven approaches in drug discovery and development, positioning Swiss companies to leverage AI for future therapeutic innovations.
Original source record. Open the original record to verify the underlying announcement.